STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
31
13F, latest reported quarter
What the filings say about ANL
Insiders, 180 days
-$411.2K net sold
3 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$1.2M
1 notice
Adlai Nortye insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Adlai Nortye Group Ltd. insiders sold a net $411.2K of stock across 7 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Foreign private issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.
First Form 4 purchase or sale (code P or S) here by this insider on our record.
The trade is 3.8% of the 131,667 shares held after it.
1 other insider sold within 30 days.
31 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Ji Ping sold about $83.2K of ANL on Sep 22, 2026; 1 other insider sold within 30 days and 31 funds added in the latest 13F quarter.
1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Aug 24, 2026.
The trade is 3.8% of the 147,757 shares held after it.
1 other insider sold within 30 days.
31 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO Ye Xiaofeng sold about $80.8K of ANL on Aug 26, 2026; 1 other insider sold within 30 days and 31 funds added in the latest 13F quarter.
7 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Nobody has filed for crossing 5%. That is a fact, not missing data.
ANL planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Ji Ping
Filed 2026-09-18
$1.2M
ANL mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus Biotech Clinical Trials Etf
$391.5K position · as of 2026-07-31
0.8%
Eventide Healthcare & Life Sciences Fund
$8.3M position · as of 2026-06-30
0.5%
Tema Oncology ETF
$529.6K position · as of 2026-05-31
0.3%
ULTRACHINA PROFUND
$15.0K position · as of 2026-07-31
0.1%
Fidelity Nasdaq Composite Index Fund
$132.9K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $411.2K sold by insiders over 180 days, 31 funds added last quarter, $1.2M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
ANL ranks highest on risk and compliance (43rd percentile) and institutional and government (39th), and lowest on insider conviction (22nd), among Pharma & Biotech peers.
Insider conviction
22
Inputs
Net Form 4 buying (codes P and S), 180d-$411K · 43 pct, sector of 428
Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
39
Inputs
Funds adding, latest quarter31 · 39 pct, sector of 698
Congress net buyers, 365dno Congress trades in 365 days
Federal contracts, 180dno federal contracts in 180 days
Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
43
Inputs
Short interest, % of float+8.9% · 43 pct, sector of 813
Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Profitability, Financial health, Growth, US patents
Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
Financial health needs 1 of 2 inputs, 0 present: no debt line filed
Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ANL filings, in plain words
Are Adlai Nortye insiders buying or selling ANL?
In the 180 days to 2026-10-28, Adlai Nortye insiders were net sellers, a net $411.2K across purchases and sales reported on Form 4, by 3 sellers.
Are there planned insider sales of ANL?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $1.2M of stock; the latest, by Ji Ping, was filed 2026-09-18.
Read the full summary
In the 180 days to 2026-10-28, Adlai Nortye insiders were net sellers of ANL, a net $411.2K across purchases and sales reported on Form 4 by 3 sellers. None of the 7 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $1.2M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address, your watchlist and your preferences, nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in and remember this choice.
Google Analytics 4 and Microsoft Clarity load only if you allow them here; they
count visits and record how pages are used. We run no advertising and never sell
data. Details in the privacy policy. Change this any time
via "Cookie settings" in the footer.
